Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL249639 | 1.00 | L3MBTL1 (0.58) | L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A | |
| Toluene SCHEMBL249116 | 1.00 | L3MBTL1 (0.58) | L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A | |
| Toluene SCHEMBL249049 | 1.00 | L3MBTL1 (0.58) | L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A | |
| Toluene SCHEMBL251831 | 1.00 | L3MBTL1 (0.58) | L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A | |
| Toluene SCHEMBL299997 | 1.00 | L3MBTL1 (0.58) | L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A | |
| Toluene SCHEMBL9462510 | 1.00 | L3MBTL1 (0.58) | L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A | |
| Toluene SCHEMBL8940231 | 1.00 | L3MBTL1 (0.58) | L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A | |
| Toluene SCHEMBL1143384 | 1.00 | L3MBTL1 (0.58) | L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A | |
| Toluene SCHEMBL16053153 | 1.00 | L3MBTL1 (0.58) | L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A | |
| Toluene SCHEMBL2053140 | 1.00 | L3MBTL1 (0.58) | L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247751-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2020-08-06 | — | — | US | disclosed |
| US-20190077755-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2019-03-14 | — | — | US | disclosed |
| US-10173978-B2 | Small molecule androgen receptor inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180215712-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2018-08-02 | — | — | US | disclosed |
| WO-2017023916-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| EP-2488601-B1 | ELECTROCHROMIC COMPOUND, ELECTROCHROMIC COMPOSITION, AND DISPLAY ELEMENT | RICOH CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2488601-A1 | ELECTROCHROMIC COMPOUND, ELECTROCHROMIC COMPOSITION, AND DISPLAY ELEMENT | Ricoh Company, Limited (JP) | 2012-08-22 | — | — | EP | disclosed |
| EP-2464667-A2 | N-ACYLATED OCTASACCHARIDES ACTIVATING FGFS RECEPTORS, THEIR SYNTHESIS AND THEIR THERAPEUTICAL APPLICATION | SANOFI (FR) | 2012-06-20 | — | — | EP | disclosed |
| EP-2464359-A2 | N-SULFATED OLIGOSACCHARIDES ACTIVATING FGFS RECEPTORS, THEIR SYNTHESIS AND THEIR THERAPEUTICAL APPLICATION | SANOFI (FR) | 2012-06-20 | — | — | EP | disclosed |
| WO-2011046222-A1 | ELECTROCHROMIC COMPOUND, ELECTROCHROMIC COMPOSITION, AND DISPLAY ELEMENT | RICOH COMPANY, LTD. (JP) | 2011-04-21 | — | — | WO | disclosed |
| US-5096897-A | Antiallergens, antiischemic agents, treatment of asthma | BAYER AKTIENGESELLSCHAFT (DE) | 1992-03-17 | — | — | US | disclosed |
| EP-0277676-B1 | NEW LL-ARYL STEROID DERIVATIVES | AKZO N.V. (NL) | 1992-03-04 | — | — | EP | disclosed |
| US-5039670-A | Anticoagulants, antiasthma, antiallergens | BAYER AKTIENGESELLSCHAFT (DE) | 1991-08-13 | — | — | US | disclosed |
| US-4943568-A | Cephalosporins | BAYER AKTIENGESELLSCHAFT (DE) | 1990-07-24 | — | — | US | disclosed |
| CN-1036774-A | 9 alpha-hydroxy-17-methylene steroids, their preparation and their use in the preparation of corticosteroids | GIST BROCADES NV (NL) | 1989-11-01 | — | — | CN | disclosed |
| WO-1989009781-A1 | 9-ALPHA-HYDROXY-17-METHYLENE STEROIDS, THEIR PREPARATION AND UTILIZATION | GIST-BROCADES N.V. (NL) | 1989-10-19 | — | — | WO | disclosed |
| EP-0336521-A1 | 9-Alpha-hydroxy-17-methylene steroids, process for their preparation and their use in the preparation of corticosteroids | ROUSSEL-UCLAF (FR) | 1989-10-11 | — | — | EP | disclosed |
| EP-0277676-A1 | New ll-aryl steroid derivatives | AKZO N.V. (NL) | 1988-08-10 | — | — | EP | disclosed |
| CN-87106868-A | 9-alpha-hydroxy steroids, process for their preparation, corresponding 9(11) -dehydro derivatives and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1988-04-27 | — | — | CN | disclosed |
| EP-0263569-A2 | 9-alpha-hydroxysteroids, process for their preparation and process for the preparation of the corresponding 9(11)-dehydro-derivatives. | ROUSSEL-UCLAF (FR) | 1988-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215712-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | AR, KLK3, BRDT | L3MBTL1 4524/4885TDP1 3192/4885SMN1; SMN2 4871/4885 |
| US-20190077755-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | AR, KLK3, BRDT | L3MBTL1 4524/4885TDP1 3192/4885SMN1; SMN2 4871/4885 |
| US-20200247751-A1 | SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | AR, KLK3, BRDT | L3MBTL1 4524/4885TDP1 3192/4885SMN1; SMN2 4871/4885 |
| US-10173978-B2 | Small molecule androgen receptor inhibitors and methods of use thereof | AR, KLK3, BRDT | L3MBTL1 4524/4885TDP1 3192/4885SMN1; SMN2 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.